Evidence map›Paper›PMID 26035554›Full record

ArticlePloS one2015

Implication of urinary complement factor H in the progression of immunoglobulin A nephropathy.

Maojing Liu, Yuqing Chen, Jingjing Zhou, Ying Liu, Fengmei Wang, Sufang Shi, Yanfeng Zhao, Suxia Wang, Lijun Liu, Jicheng Lv and 2 more

Open access · goldAbstract readClinical Study
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Deletion Variants ofJournal of the American Society of Nephrology : JASN · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Maojing LiuRenal Division, Department of Medicine, Peking University First Hospital; Beijing 100034, China; Institute of Nephrology, Peking University; Beijing 100034, China; Key Laboratory of Renal Disease, Ministry of Health of China; Beijing 100034, China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education; Beijing 100034, China.
Yuqing ChenRenal Division, Department of Medicine, Peking University First Hospital; Beijing 100034, China; Institute of Nephrology, Peking University; Beijing 100034, China; Key Laboratory of Renal Disease, Ministry of Health of China; Beijing 100034, China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education; Beijing 100034, China.
Jingjing ZhouRenal Division, Department of Medicine, Peking University First Hospital; Beijing 100034, China; Institute of Nephrology, Peking University; Beijing 100034, China; Key Laboratory of Renal Disease, Ministry of Health of China; Beijing 100034, China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education; Beijing 100034, China.
Ying LiuRenal Division, Department of Medicine, Peking University First Hospital; Beijing 100034, China; Institute of Nephrology, Peking University; Beijing 100034, China; Key Laboratory of Renal Disease, Ministry of Health of China; Beijing 100034, China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education; Beijing 100034, China.
Fengmei WangRenal Division, Department of Medicine, Peking University First Hospital; Beijing 100034, China; Institute of Nephrology, Peking University; Beijing 100034, China; Key Laboratory of Renal Disease, Ministry of Health of China; Beijing 100034, China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education; Beijing 100034, China.
Sufang ShiRenal Division, Department of Medicine, Peking University First Hospital; Beijing 100034, China; Institute of Nephrology, Peking University; Beijing 100034, China; Key Laboratory of Renal Disease, Ministry of Health of China; Beijing 100034, China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education; Beijing 100034, China.
Yanfeng ZhaoRenal Division, Department of Medicine, Peking University First Hospital; Beijing 100034, China; Institute of Nephrology, Peking University; Beijing 100034, China; Key Laboratory of Renal Disease, Ministry of Health of China; Beijing 100034, China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education; Beijing 100034, China.
Suxia WangLaboratory of Electron Microscopy, Peking University First Hospital, Peking University First Hospital; Beijing 100034, China.
Lijun LiuRenal Division, Department of Medicine, Peking University First Hospital; Beijing 100034, China; Institute of Nephrology, Peking University; Beijing 100034, China; Key Laboratory of Renal Disease, Ministry of Health of China; Beijing 100034, China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education; Beijing 100034, China.
Jicheng LvRenal Division, Department of Medicine, Peking University First Hospital; Beijing 100034, China; Institute of Nephrology, Peking University; Beijing 100034, China; Key Laboratory of Renal Disease, Ministry of Health of China; Beijing 100034, China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education; Beijing 100034, China.
Hong ZhangRenal Division, Department of Medicine, Peking University First Hospital; Beijing 100034, China; Institute of Nephrology, Peking University; Beijing 100034, China; Key Laboratory of Renal Disease, Ministry of Health of China; Beijing 100034, China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education; Beijing 100034, China.
Minghui ZhaoRenal Division, Department of Medicine, Peking University First Hospital; Beijing 100034, China; Institute of Nephrology, Peking University; Beijing 100034, China; Key Laboratory of Renal Disease, Ministry of Health of China; Beijing 100034, China; Key Laboratory of Chronic Kidney Disease Prevention and Treatment, Ministry of Education; Beijing 100034, China.
Peking University · CNPeking University First Hospital · CNKing University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAfter activation, the complement system is involved in the pathogenesis of Immunoglobulin A nephropathy (IgAN). Complement factor H (CFH) is a crucial inhibitory factor of the alternative pathway of the complement system. The study investigated the effects of urinary CFH levels on IgAN progression.

methodsA total of 351 patients with IgAN participated in this study. They were followed up for an average of 51.8 ± 26.6 months. Renal outcome was defined as a composite endpoint, that included instances of end-stage renal disease (ESRD), ≥ 50% decline in estimated glomerular filtration rate (eGFR) or doubling of plasma creatinine levels. Urinary CFH levels were measured by enzyme-linked immunosorbent assay and calculated as the ratio of urinary CFH over creatinine (uCFH/uCr).

resultsIn the whole cohort, uCFH/uCr values were associated with disease progression either as continuous [log(uCFH/uCr)] or categorical traits (dichotomous and quartile variables) after adjusting for eGFR, proteinuria, mean arterial blood pressure, histological grading and immunosuppressive therapy in the Cox proportional hazard model. Kaplan-Meier analysis showed that higher uCFH/uCr values at baseline predicted worse renal outcome during follow-up (log-rank, P < 0.001). Receiver operating characteristic curve (ROC) analysis showed that log(uCFH/uCr) had predictive value for renal outcome (area under curve [AUC] = 0.745), and the AUC increased to 0.805 after being incorporated into baseline eGFR and proteinuria. In subgroup analysis with eGFR ≥ 60 mL/min/1.73 m2, log(uCFH/uCr) had better predictive value (AUC = 0.724, P = 0.002) for renal outcome compared to eGFR (AUC = 0.582, P = 0.259) and proteinuria (AUC = 0.615, P = 0.114).

conclusionsUrinary CFH levels are associated with renal function decline and increased urinary CFH levels are a risk factor for progression of IgA nephropathy.

Indexed as

AdultCohort StudiesComplement Factor HFemaleGlomerular Filtration RateGlomerulonephritis, IGAHumansKaplan-Meier EstimateKidney Failure, ChronicMaleMiddle AgedROC CurveComplement Factor H

Identifiers

PMID26035554
PMCPMC4452759
OpenAlexW589229573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.